- SID Score
- 7.4/10
- Fair value
- $64.29
- Generated
- Oct 25, 2026
- Model
- claude-haiku-4-5-20251001
AbbVie Inc. trades at $285.64 with a market capitalization of $410.1 billion, positioning it as a major player in the healthcare sector. The stock displays significant overvaluation concerns with a P/E ratio of 97.75 and a fair value estimate of $64.29, suggesting the current price exceeds intrinsic value by 77.5%. While the company maintains a respectable 2.87% dividend yield and holds a SID score of 7.4/10, the valuation metrics present considerable risk for value-conscious investors despite mixed positive fundamentals in growth and momentum categories.
AbbVie demonstrates mixed financial performance with recent earnings showing inconsistency—Q3 2026 EPS came in below estimates at 3.65 versus 3.77, and Q2 2026 slightly underperformed at 2.65 versus 2.66 estimated. The company receives a profitability grade of C, suggesting mediocre earnings quality despite its substantial market capitalization, while growth prospects are rated B indicating moderate expansion potential. The most alarming metric is the extremely elevated P/E ratio of 97.75x, which implies the market is pricing in either unrealistic future growth or significant overvaluation relative to current earnings power.
The stock is trading significantly above both its 50-day moving average of $266.12 and 200-day moving average of $236.30, indicating a sustained uptrend but also extended price momentum. With an RSI(14) reading of 70.9, AbbVie is in overbought territory, suggesting potential for near-term pullback or consolidation as the indicator approaches the 70+ threshold typically associated with excessive buying pressure. The price momentum remains strong on a relative basis, earning a B grade, though this technical strength appears disconnected from fundamental valuation metrics.
Analyst & Insider Sentiment
The analyst consensus maintains a "Buy" rating with an average price target of $258.83, representing a 9.4% downside from current levels and suggesting analysts see limited upside despite their positive stance. Insider activity reveals persistent buying behavior, with executives Edward J. Rapp and Susan E. Quaggin making substantial purchases throughout 2026, most notably Rapp's acquisition of 29,236 shares on June 30, 2026, signaling management confidence in long-term value. However, the gap between the analyst consensus target and current price, combined with the discrepancy between insider confidence and fundamental valuations, creates conflicting signals.
The primary risk is severe valuation risk, with the stock trading at nearly 4.5x the estimated fair value of $64.29, leaving minimal margin of safety for investors and significant downside potential if market sentiment shifts. Earnings quality concerns are evident from recent misses and the C-grade profitability rating, suggesting operational challenges or margin pressures that could continue to disappoint market expectations. Additionally, the overbought technical condition (RSI 70.9) combined with analyst price targets below current levels indicates near-term correction risk, and the lack of recent financial data raises questions about transparency and investor confidence.
AbbVie presents a cautionary tale of a mature healthcare company with attractive dividend yields (2.87%) and insider support, but fundamentally overvalued at current prices relative to its earnings power and growth prospects. The 77.5% gap between current price and fair value estimate, combined with overbought technical conditions and analyst price targets implying downside, suggests the risk-reward profile is unfavorable for new investors. For existing shareholders, holding may be justified by the dividend yield and insider confidence, but for new investors, waiting for a more attractive entry point near the $258-$265 analyst target range or demonstrating significant operational improvement would be prudent before committing capital.
